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We developed a new biological cloning system for HIV-1 isolates using the U87.CD4 cell lines that express different chemokine receptors. We
demonstrate that our method is sensitive and specific because the clones isolated had the same coreceptor usage and genotype as viruses of the
primary isolate. We evaluated our cloning system by isolating 27 biological clones from two primary HIV-1 R3R5X4 isolates. Three HIV-1
phenotypes (R3R5X4, R3R5 and R5) were identified in isolate 29 and two (R3R5X4 or R5X4) in isolate 31. Each phenotype was distinguished by
a unique genotype. Sequencing of 20 molecular clones from each isolate did not reveal additional genotypes. One of the three genotypes identified
from isolate 29 was not found by molecular cloning of the original isolate, suggesting high specificity and sensitivity of the biological cloning
system in isolating minor virus populations. Our results suggest that the new cloning approach can be used as an alternative to the existing method
for isolating biological clones in PBMC.
© 2006 Elsevier Inc. All rights reserved.Keywords: Biological cloning; HIV-1; CoreceptorsIntroduction
Human immunodeficiency virus type 1 (HIV-1) infects cells
of the T-cell and macrophage lineages (Dalgleish et al., 1984;
Folks et al., 1986; Gartner et al., 1986; Klatzmann et al., 1984).
At the cell surface, the viral envelope (Env) glycoprotein (gp)
120 interacts with CD4 and a chemokine coreceptor. This
interaction results in a series of conformational changes in both
the gp120 and gp41 which allows the virus to enter the cell
(Berger, 1997). HIV-1 has been defined as being fast or slow
replicating in peripheral blood mononuclear cells (PBMC) (Asjo
et al., 1986; Fenyo et al., 1988) or as having the capacity to
induce syncytia in PBMC or MT-2 cells (called syncytium
inducing, SI and non-syncytium inducing, NSI, respectively)
(Tersmette et al., 1988). The molecular basis for the phenotypic
differences of HIV-1 is due to the ability of the virus to use⁎ Corresponding author. Department of Laboratory Medicine, Division of
Medical Microbiology/Virology, Lund University, Sölvegatan 23, 223 62 Lund,
Sweden. Fax: +46 46 176033.
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doi:10.1016/j.virol.2006.02.008different coreceptors. Nowadays, it is common that HIV-1 iso-
lates are classified as belonging to different phenotypes by their
ability to use different chemokine receptors as coreceptors (Berger
et al., 1998; Choe et al., 1996; Deng et al., 1996; Doranz et al.,
1996; Feng et al., 1996). Early in infection, HIV-1 most often
uses CCR5 as coreceptor and these viruses are called R5 viruses.
Later in the infection, coreceptor usage of viruses may change to
CXCR4 and these viruses are termed X4 viruses. The viruses
may also broaden their coreceptor repertoire into using a combi-
nation of CCR5, CXCR4 and other minor chemokine receptors,
mostly CCR3. In infected individuals, a switch of coreceptor
usage is often associated with an accelerated loss of CD4+ T-cells
and progression towards clinical symptoms characteristic of ac-
quired immunodeficiency syndrome (AIDS) (Bjorndal et al.,
1997; Connor et al., 1997; Scarlatti et al., 1997; Yu et al., 1998).
The viral population of an infected individual consists of a
swarm of genetically related viruses which are termed quasi-
species. Quasi-species likely arise by at least two mechanisms;
first, the viral replication machinery is error prone because the
viral reverse transcriptase lacks proof reading ability, and
second, there is continuous rapid virus turn over. While
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about the impact of quasi-species on the biological variability of
HIV-1. Early work showed that SI (CXCR4-using) isolates are
composed of both SI and NSI phenotypic variants (Schuite-
maker et al., 1992). In agreement with these observations, we
have previously shown that viruses with different coreceptor
usage can be selected by limited passage in single coreceptor
expressing cells (Bjorndal et al., 1997; Scarlatti et al., 1997).
Coreceptor evolution plays an important role in HIV-1
pathogenesis and there is a clear correlation between appearance
of CXCR4 usage and progression towards AIDS (Bjorndal et al.,
1997; Karlsson et al., 1994; Koot et al., 1993).
In-depth studies on biological clones, rather than primary
isolates, are important and may reveal features of the pathogenic
process. It is common practice to isolate HIV-1 biological clones
using PHA-stimulated peripheral blood mononuclear cells
(PBMC) (Schuitemaker et al., 1992). Although PBMC express
the major coreceptors of HIV-1, they are present at unequal
densities on the cell-surface. CXCR4 is expressed earlier after
stimulation and at higher levels than CCR5, whereas CCR3 is
only expressed at low levels (Bleul et al., 1997). This uneven
coreceptor densitymay lead to a positive selection for X4 viruses
at the expense of viruses with other coreceptor preference in
PBMC.
To avoid selection due to uncontrolled coreceptor avail-
ability, we have developed an alternative method for isolating
biological clones using the U87.CD4-system. Isolation of bio-
logical clones is performed by dilutions of viral isolates in the
presence of only one coreceptor at a time.
Results presented here, using two multitropic R3R5X4 pri-
mary HIV-1 isolates, show that our method accurately identifies
viral clones having the same biological and molecular properties
as the primary isolates. In addition, our approach is faster and
less labor intensive than conventional cloning in PBMC.Fig. 1. Schematic picture of the selective biological cloning system. (A) First selecti
times on U87.CD4-CCR3, -CCR5 and -CXCR4 expressing cells. (B) Second select
-CCR5 and -CXCR4-expressing cells in a second selection step. (C) Genotypic det
second selection, was amplified and sequenced. (D) Phenotypic determination: con
determined by infection of U87.CD4 cell lines.Results
Cloning strategy and biological properties of the isolates
In comparison to PBMC, syncytia formation is easily de-
tected in U87 cells. Cultures showing 5 or less syncytia per
well were defined as having low degree of syncytia formation
(LDSF). As is described below, the LDSF definition allowed
us to successfully identify biological clones without determin-
ing classical “end-points” that is common practice in PBMC-
based cloning. Two HIV-1 primary isolates (29 and 31) were
first diluted and passaged in four parallel wells on U87.CD4
cells expressing either CCR3, CCR5 or CXCR4 coreceptors.
Cultures were analyzed for syncytia formation and RT activity
at day 6 (for CCR5 and CXCR4 expressing cells) or at day 10
(for CCR3 expressing cells).
After first passage, the isolates reached LDSF at different
dilutions on the different cell lines (Figs. 2 and 3). Isolate 29
scored highest both by RT and syncytia formation on CCR5-
expressing cells (Fig. 2) whereas isolate 31 showed highest titer
on CXCR4-expressing cells (Fig. 3). Isolate 29 infected CCR3-
expressing cells to about the same extent as CXCR4-expressing
cells (Fig. 2), whereas isolate 31 infected CCR3-expressing cells
at comparatively lower dilutions (Fig. 3).
Isolation of biological clones
Virus supernatants from the first passage were subjected to a
second selection step by infection of the three U87.CD4
coreceptor expressing cell lines. Proviral DNA was obtained
from cells in the second selection step. A 300-bp region
containing the V3 region of env was amplified and genotypes
were determined by direct sequencing (Fig. 1). Direct
sequencing of isolate 29 showed many heterogenic sites (Fig.on step: in the first selection step, virus isolates were diluted and passaged 1–3
ion: supernatants from first selection step were used to infect U87.CD4-CCR3,
ermination: to confirm clonality, V3 region from proviral DNA, obtained after
firmed biological clones were grown on PBMC and the phenotype was finally
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selection were homogenous (for example, 29A in Fig. 4B and
29B in Fig. 4C) whereas a few were mixtures of genetically
distinct variants (for example, clone 29X2 in Fig. 4D).
We observed a correlation between dilution of isolate 29 in
the first passage and homogenous nucleotide sequence after
second selection (exceptions were clones 29E1–3, see below).
Isolate 29 passaged (diluted 33-fold) on CCR3-expressing cells
had heterogeneous genotype after the second selection step
(Table 1, 29 X1–3). However, when LDSF was reached in the
first passage (diluted both 35- and 36-fold) we observed homo-
genous genotypes (Table 1, clones 29A1–3 and 29B1–2, respec-
tively). For clarity, only the V3 region is shown but clonality
was observed over the entire 300-bp region sequenced. The
same pattern was observed when viruses were selected on
CCR5-expressing cells. In this case, the first passage of isolate
29 (a 33-fold dilution) on CCR5-expressing cells resulted in a
mixed genotype (Table 1, 29X4–6), whereas virus that reached
LDSF in first passage (diluted 4 × 35-fold) showed homoge-
nous genotypes (Table 1, clones 29C1–3). The genotype of
29C1–3 seemed to depend on the cells used in the second
selection. Clones 29C1 and 29C3 were harvested from CCR3
and CXCR4-expressing cells, respectively, and both had
genotype I, whereas clone 29C2 which was isolated from
CCR5 expressing cells had genotype II. This observation
suggested that the virus population, although highly diluted in
the first step, was still heterogeneous and could be further
selected in the second step. All clones obtained from CXCR4-Table 1
Generation of biological clones, isolate 29
Isolate 29 was diluted and passaged on U87.CD4 cells expressing CCR3, CCR5 or
was isolated from cells in second selection, PCR amplified and the V3 region was s
sequence. b: Co-receptor expression of U87.CD4 cells used for first passage. c: Co-re
acid sequence of V3 loop, denotes heterogenic sites. Mixed, denotes a non-clonal seqexpressing cells had a homogenous genotype (Table 1 29E1–3
and 29F1–3) that was independent of dilution factor.
The genotype of isolate 31 was less complex compared to
isolate 29 and displayed only two heterogeneous amino acid
sites (Table 2). Both alternative sites were identified in the
biological clones (genotype IV and V, respectively) obtained
with the selective cloning system described here. As described
above for isolate 29, the efficiency for obtaining biological
clones increased with the dilution factor in the first passage
(Table 2).
Phenotypes of the biological clones
We next determined the phenotypes of the biological
clones which we isolated using the U87-cloning system. Virus
supernatants from the second selection were used to prepare
viral stocks in PBMC. The phenotypes of the biological
clones were determined by infecting the coreceptor expressing
U87.CD4 cells with virus supernatant derived from the viral
stocks. We found that isolate 29 was composed of viruses
with an R3R5X4 or R3R5 phenotype, with the majority of
clones being R3R5X4 (Table 1). Isolate 31 appeared to have
R3R5X4 and an R5X4 population (Table 2). Interestingly, the
R3R5X4 phenotype was only obtained when the first passage
of isolate 31 was performed on CCR3 expressing cells.
Sequence analysis showed that the charge of the V3 region
differed among the biological clones. All clones from isolate
31 had a charge of +5 (Table 2) and clones from isolate 29CXCR4, followed by a second selection on the three U87.CD4 cell lines. DNA
equenced. a: Designation of clone, X represents a clone with heterogeneous V3
ceptor expression of U87.CD4 cells used in the second selection step. d: Amino
uence. e: Phenotype of biological clone.
Table 2
Generation of biological clones, isolate 31
Isolate 31 was diluted and passaged on U87.CD4 cells expressing CCR3, CCR5 or CXCR4, followed by a second selection on the three U87.CD4cell lines. DNA
was isolated from cells in second selection, PCR amplified and the V3 region was sequenced. a: Designation of clone, X represents a clone with heterogeneousV3
sequence. b: Co-receptor expression of U87.CD4 cells used for first passage. c: Co-receptor expression of U87.CD4 cells used in the second selection step. d: Amino
acid sequence of V3 loop ?, denotes heterogenic site. Mixed, denotes a non-clonal sequence. e: Phenotype of biological clone.
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R5 populations were not identified from any of the isolates
by the method described here. This observation was
surprising since isolate 29 reached highest titers on CCR5-
expressing cells. We therefore subjected both isolates to serial
passages on CCR5-expressing cells using diluted virus at
each passage.
Serial dilutions on CCR5-expressing cells
Three consecutive dilutions were done on CCR5-expres-
sing cells. In each passage, LDSF was reached and
supernatant from the serial passages was subjected to a
second selection step on CCR3, CCR5 and CXCR4
expressing cells (Fig. 1). By this approach, we isolated
three R5 clones and one R3R5 clone (with weak CCR3
usage) from isolate 29 (Table 3, clones 29a–d). All four clones
had identical sequence (genotype III). Genotype III displayed
the triplet AAA (data not shown) corresponding to a lysineTable 3
Generation of biological clones from isolate 29 by serial dilutions on CCR5-express
Isolate 29 was diluted and passaged three times on U87.CD4-CCR5 cells followed
The phenotype of biological clones isolated was determined and the V3 region w
second selection step. c: V3 loop amino acid sequence of. d: Phenotype of biolog(K) in amino acid position 18 (Table 3), whereas genotypes I
and II had the triplet AGG and AGA (data not shown),
respectively, both coding for an arginine (R) (Tables 1 and
2). Amplification and direct sequencing of DNA from isolate
29 identified a heterogenic site (the triplet AGG or AGA) in
position 18. Thus, the AAA triplet of genotype III was not
identified by direct sequencing which suggested that
genotype III represented a minor fraction of the total
(Leitner et al., 1993). The charge of the V3 region of
genotype III was +4.
Serial dilution and passages on CCR5-expressing cells of
isolate 31 confirmed the R5X4 phenotype of genotype V but we
did not identify clones with pure R5 phenotype (data not
shown).
Confirmation of genotypes
To confirm that the genotypes identified from the
biological clones existed in the original isolates, we amplifieding cells
by a second selection on U87.CD4 cells expressing CCR3, CCR5 or CXCR4.
as amplified and sequenced. a: Designation of clone. b: Cell line used in the
ical clone. Phenotype in parenthesis indicates weak coreceptor usage.
Fig. 2. Isolate 29 was diluted and passaged on U87.CD4-CCR3, -CCR5 and
-CXCR4 expressing cells. Cultures were analyzed for syncytia formation and
RT activity in supernatants on day 6 for CCR5- and CXCR4-expressing cells
and on day 10 for CCR3-expressing cells. RT activity (a) and score of syncytia
(B) in isolate 29 infected U87.CD4-CCR3, -CCR5 and -CXCR4 expressing
cells. (A) Mean absorbance values for RT activity in supernatants from
quadruplicate wells. (B) Mean score of syncytia in quadruplicate wells. Syncytia
formation was scored as 3, large syncytia covering >50% of the well; 2, large
syncytia covering <50% of the well; 1, ≤5 small occasional syncytia (LDSF).
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isolates 29 and 31. Sequencing of 20 clones from each isolate
confirmed all genotypes which were identified from the
biological clones. The only exception was genotype III of
isolate 29 (see above), again suggesting that this genotype
represented a minor population. In addition, we did not
identify additional genotypes in the original isolate compared
to those isolated by biological cloning.
Discussion
We have developed an alternative method for isolating
biological clones from primary HIV-1 isolates by using U87.
CD4 cells expressing coreceptors. Biological clones are
commonly isolated by limiting dilutions on human PBMC
(Schuitemaker et al., 1992). Briefly, primary isolates or
infected PBMC are cocultivated in 96-well plates with PHA-
stimulated PBMC from healthy blood donors. The proportion
(F) of infected cells is determined from the formula for the
Poisson distribution, F = −ln(F0), where F0 is the fraction of
negative cultures. Only virus clones obtained from a dilution
that gives rise to progeny virus in fewer than 33% of parallel
cultures are considered clonal. The data presented here
suggests that our cloning system can be used as an alternative
method to the existing PBMC method. The main difference
between the two methods is the cells used for selection. U87 is
a human glioma cell line that has been engineered to express
CD4 and either CCR3, CCR5 or CXCR4. PBMC also express
these coreceptors but at different levels. CXCR4 is more highly
expressed than CCR5 and CCR3 is only expressed at low levels.
Therefore, passage of virus isolates on PBMC will select for
variants that use CXCR4 and against variants that use CCR5
and particularly those using CCR3, for example, R3R5 variants.
Thus, virus variants present in small amounts and not able to use
CXCR4 as a coreceptor will statistically be time and resource
consuming to isolate. Our method isolated variants with only
one coreceptor present at a time. In this way, the biological
properties of each virus variant are taken into account and the
probability to isolate variants other than CXCR4-using viruses
will be higher.
Another advantage of the U87.CD4-system is that syncytia
are easily detected after infection with HIV. Our results showed
a correlation between isolation of biological clones, RT-activity
and LDSF in the first passage. In addition, when LDSF was
reached in the first passage, proviral DNA had homogenous
sequences after the second selection step. Conversely, when
LDSF was not reached in first passage, the identified
sequences after the second selection were mixtures of more
than one genotype. Therefore, LDSF alone is a good indicator
of clonality and RT activity or other costly screening methods
do not have to be used after the first passage. Thus, our
protocol allows for fast and non-expensive selection of HIV-1
clones.
We evaluated our system using two multitropic R3R5X4
primary HIV-1 isolates (29 and 31). We obtained 18 clones from
isolate 29 and 9 clones from isolate 31. The two isolates differed
in their efficiency of infecting the different coreceptor expres-sing cell lines (Figs. 2 and 3). Isolate 31 reached highest titers on
CXCR4-expressing cells while isolate 29 titrated to highest
levels on CCR5-expressing cells. Viruses of isolate 29 infected
CCR3-expressing cells more efficiently than viruses of isolate
31. Clones isolated from the two isolates reflected these
differences. Isolate 29 had clones with R5, R3R5 or R3R5X4
phenotypes, whereas clones from isolate 31 were of R5X4 or
R3R5X4 phenotypes (Table 4).
Direct sequencing of amplification products from the two
isolates revealed 6 and 2 heterogenic amino acids sites in isolates
29 and 31, respectively, in the V3 region (Tables 1 and 2,
respectively). The efficiency of our method in generating
biological clones is illustrated by the fact that the heteroge-
neous (mixed) genotypes of the isolates were separated into
different biological clones, each having a homogenous
sequence that accounted for the heterogeneous sites we
observed in the original isolate (Fig. 4). We also observed
that the efficiency in generating biological clones increased
with virus dilution in first passage (Tables 1 and 2). However,
we were able to isolate biological clones (29E1–3) when low
dilution (3 fold) of isolate 29 was used in first passage on
Fig. 3. Isolate 31 was diluted and passaged on U87.CD4-CCR3, -CCR5 and
-CXCR4-expressing cells. Cultures were analyzed for syncytia formation and
RT activity in supernatants on day 6 for CCR5- and CXCR4-expressing cells
and on day 10 for CCR3-expressing cells. RT activity (A) and score of
syncytia (B) in isolate 31 infected U87.CD4-CCR3, -CCR5 and -CXCR4
expressing cells. (A) Mean absorbance values for RT activity in supernatants
from quadruplicate wells. (B) Mean score of syncytia in quadruplicate wells.
Syncytia formation was scored as 3, large syncytia covering >50% of the
well; 2, large syncytia covering <50% of the well; 1, ≤5 small occasional
syncytia (LDSF).
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cloning system takes biological properties into account and
CXCR4-using viruses were only represented by R3R5X4Table 4
Summary of phenotypic and genotypic differences
a Phenotype of biological clones. Phenotype in parenthesis indicates weak corecept
b Genotype of bilogical clones.
c Amino acid sequence of the V3 loop.
d Overall charge of the V3 loop.viruses in isolate 29. In other words, the R3R5X4 virus
population did not have to compete with other X4 strains for
the CXCR4 receptor on the cells used for first passage and
lower dilutions of isolate 29 were not required to isolate
biological clones on CXCR4.
Sequence analysis of the biological clones revealed 3
different genotypes in isolate 29 (genotypes I–III) and two in
isolate 31 (genotypes IV and V). We found a correlation
between the number of charged amino acids of the V3 loop
and phenotype. CXCR4-using clones of isolate 29 had high
V3 charge (+6) and a basic amino acid in position 25,
whereas clones with a lower V3 charge used other
coreceptors (Table 4). This observation is in agreement with
several previous studies suggesting that a high V3 loop
charge (De Jong et al., 1992a, 1992b; Fouchier et al., 1992)
and a basic amino acid in position 25 (De Jong et al., 1992a,
1992b; Fouchier et al., 1995; Shioda et al., 1992) are
associated with CXCR4 usage.
To confirm that the biological cloning system indeed selected
variants preexisting in the isolate, we molecularly cloned and
sequenced 20 clones from each isolate. In isolate 31, we iden-
tified all genotypes by cloning. Clones from isolate 29 were
represented by genotypes I and II, but not genotype III. Since
clones with genotype III (R5 phenotype) were derived through
serial passage in CCR5-expressing cells, the question may arise
whether this genotype is a result of mutations acquired during
passages. This is highly unlikely since analysis of regions
adjacent to the V3 loop from clones with genotype III, revealed
several other positions that differed from sequences of other
clones (data not shown). Generation of these mutations would
most likely have required longer time and far more passages than
we have performed. Most probably, genotype III represents a
minor population (none of the 20 clones sequenced had this
genotypewhich roughly correspond to <5% of the isolate) which
confirms the selective power of our cloning system.
In this work, we have focused on analyzing clones with
respect to coreceptor usage. Another important biological
property is the sensitivity to neutralization. Broad resistance
to neutralizing antibodies is typically lost when viruses are
adapted to growth in permanent T-cell lines (Sawyer et al.,
1994; Zhang et al., 1997). Moreover, a recent study showedor usage.
Fig. 4. Nucleotide sequences corresponding to amino acids 13–25 of the V3
loop. (A) Isolate 29; (B) biological clone 29A. (C) biological clone 29B; (D)
heterogeneous sequence 29X2. The arrow ( ) indicates heterogenic site.
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(Beaumont et al., 2004). The decreased resistance to
neutralizing antibodies observed may be due to the acquisi-
tion of a more open conformation of gp120 during passage
(Poignard et al., 2001). This suggests that limiting the number
of passages in vitro is of greater importance than the choice
of cells when isolating biological clones from primary HIV-1
isolates.
The data presented here demonstrate that our new method for
isolating biological clones is sensitive and specific because the
clones isolated had the same coreceptor usage and genotype as
viruses of the primary isolate. We also found that our method is
fast and non-labor intensive and suggest that the method can be
used as an alternative to the existing method for isolating
biological clones in PBMC cultures.
Materials and methods
Patients and virus isolates
Virus isolates 29 and 31 (Asjo et al., 1986; Fenyo et al., 1988)
were obtained from patients with progressive HIV-1 infection
and were passaged in PBMC not more than twice. The isolateshave previously been shown to use CCR3, CCR5 and CXCR4 as
coreceptors and were designated as R3R5X4multitropic isolates
(Bjorndal et al., 1997).
Viral stocks
Viral stocks were produced in phytohemagglutinin P (PHA-
P) (Becton Dickinson and Co., USA) stimulated human PBMC.
Briefly, 106 cells in 15 ml tubes (TPP; Switzerland) were
infected with 2 ml or 900 μl of virus supernatant obtained after
the second selection step. The cell/virus mixtures were
incubated at 37 °C and 5% CO2 for 2 h followed by addition
of 2 ml of RPMI medium (Gibco, Paisley United Kingdom)
supplemented with 10% fetal bovine serum (FBS; Hyclone,
Argentina), 2 μg/ml polybrene (PB; Sigma, Germany), 5 U of
recombinant interleukin-2 (IL-2; Amersham Biosciences,
Uppsala, Sweden) and penicillin/streptomycin (PEST; Gibco,
Paisley, United Kingdom). The day after infection, the cells
were washed with 4 ml of phosphate-buffered saline (PBS;
Gibco, Paisley United Kingdom) and resuspended in 10 ml of
fresh RPMI medium and transferred to 25 cm2 (TPP; Switzer-
land) culture flasks. The cultures were incubated at 37 °C and
5% CO2 for 7 days before virus was harvested.
Cell lines
U87.CD4 cells stably transfected with CCR3, CCR5 or
CXCR4 were kindly provided by Dr. Dan Littman (Deng et al.,
1996). Cell lines were maintained in Dulbecco's modified
Eagle's medium (Gibco, Paisley, United Kingdom) supplemen-
ted with 10% FBS and antibiotics. Cultures were grown in
25 cm2 tissue culture flasks and split at a ratio of 1:2 twice
weekly by treatment with 5 mM EDTA.
First passage
U87.CD4 cells expressing CCR3, CCR5 or CXCR4 were
seeded at a density of 105 cells/well in 24-well plates (TPP;
Switzerland) 1 day prior to infection. For infection of CCR3 and
CXCR4 expressing cells, virus isolates were diluted in six 3-fold
dilution steps, beginning with a 3-fold dilution. For CCR5-
expressing cells, the dilution steps were 33, 34, 2 × 34, 4 × 34,
8 × 34 and 4 × 35-fold. Four parallel wells were infected with
400 μl of each dilution. Cells were washed with PBS and 2 ml of
fresh mediumwas added day 1. At day 6 for CCR5 and CXCR4-
expressing cells or at day 10 for CCR3-expresssing cells, post-
infection cultures were observed for syncytia formation and
50μl of supernatants was used for reverse transcriptase (RT) assay
(Cavidi Tech AB, Uppsala, Sweden). Remaining culture super-
natants were stored at −70 °C for future experiments (Fig. 1).
In addition, we performed three consecutive dilutions with
isolate 29 and 31 on U87.CD4-CCR5-expressing cells.
Second selection
In the second selection, 5 × 104 U87.CD4 cells expressing
CCR3, CCR5 or CXCR4 were seeded in 48-well plates (TPP;
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200 μl of supernatant from first passage was used to infect
the three U87.CD4 cell lines. Prior to infection, supernatants
from the first passage were treated with 300 Units DNase/ml
(Invitrogen, Carlsbad, CA, USA) for 30 min at room
temperature. At day 1, the cells were washed with 1 ml of
PBS and 1 ml of fresh medium was added. Supernatants were
harvested at day 6 (CCR5 and CXCR4 expressing cells) or at
day 10 (CCR3-expressing cells) and used for growing viral
stocks in PBMC (Albert et al., 1990) and to prepare DNA
(Fig. 1).
Determination of coreceptor usage of biological clones
Virus supernatants, containing 5 ng of p24 from viral stocks
produced in PBMC, were used to infect U87.CD4 cells ex-
pressing CCR3, CCR5 or CXCR4. At day 6 or at day 10, cultures
were observed for syncytia formation and supernatants were
analyzed for RT activity.
PCR and sequencing
DNA was isolated using the Qiagen DNA preparation kit
(QIAGEN, Germany) according to the manufacturer's instruc-
tions. An approximately 300-bp region of env (including the
V3 region) was amplified with a nested PCR approach using
Pfu Turbo (Stratagene, USA) (Fig. 1). The outer primers were
JA167 (5′-TATCC/TTTTGAGCCAATTCCC/TATACA) and
JA170 (5′-GTGATGTATTA/GCAA/GTAGAAAAATTC) and
the inner primers were JA168 (5′-ACAATGC/TACACATG-
GAATTAA/GGCCA) and JA169 (5′-AGAAAAATTCC/
TCCTCC/TACAATTAAA) (Leitner et al., 1996). The outer
PCR was carried out as follows: one initial denaturation step
of 94 °C for 5 min, followed by 30 cycles of 94 °C for 15 s,
40 °C for 15 s and 72 °C for 1 min and a final extension at
72 °C for 5 min. The inner PCR protocol was as follows: an
initial denaturation step of 94 °C for 5 min, followed by 40
cycles of 94 °C for 15 s, 45 °C for 15 s, 72 °C for 1 min and
a final extension at 72 °C for 5 min. Sequencing was done by
using Big Dye Termination kit (Applied biosystems; Foster
City, USA) as described by the manufacturer (Fig. 1), using
60 ng of DNA and primers JA168 and JA169. Sequences
were analyzed using Chromas (http://www.technelysium.com.
au/chromas.html), ClustalX (Thompson et al., 1997) and
GeneDoc (http://www.psc.edu/biomed/genedoc). The entire
approximately 300-bp region (including the V3 region) of
env was analyzed. In Tables 1–4, we show the V3 region
only.
Molecular cloning and sequencing of the V3 region
Proviral DNA derived from infected PBMCwas amplified as
described above. PCR products were A-tailed by incubation at
72 °C for 10 min with 7.5 U of Taq polymerase (Invitrogen),
1.25 mM dATP and cloned using the Easy-T cloning kit
(Promega Corporation, Madison, USA). Selected clones were
amplified and sequenced as described above.Sequence data
Sequences have been deposited in Genbank under accession
numbers AY850200–AY850217 (isolate 29); and AY850218–
AY850224 (isolate 31).
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